<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment and prevention of hyperkalemia in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment and prevention of hyperkalemia in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment and prevention of hyperkalemia in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David B Mount, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard H Sterns, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 01, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hyperkalemia is a common clinical problem that is most often a result of impaired urinary potassium excretion due to acute or chronic kidney disease (CKD) and/or disorders or drugs that inhibit the renin-angiotensin-aldosterone system (RAAS). Therapy for hyperkalemia due to potassium retention is ultimately aimed at inducing potassium loss [<a href="#rid1">1-3</a>].</p><p>In some cases, the primary problem is movement of potassium out of the cells, even though the total body potassium may be reduced. Redistributive hyperkalemia most commonly occurs in uncontrolled hyperglycemia (eg, diabetic ketoacidosis or hyperosmolar hyperglycemic state). In these disorders, hyperosmolality and insulin deficiency are primarily responsible for the transcellular shift of potassium from the cells into the extracellular fluid, which can be reversed by the administration of fluids and insulin. Many of these patients have a significant deficit in whole body potassium and must be monitored carefully for the development of hypokalemia during therapy. (See  <a class="medical medical_review" href="/z/d/html/1795.html" rel="external">"Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Treatment", section on 'Potassium replacement'</a>.)</p><p>The treatment and prevention of hyperkalemia will be reviewed here. The causes, diagnosis, and clinical manifestations of hyperkalemia are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2377.html" rel="external">"Causes and evaluation of hyperkalemia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2342.html" rel="external">"Clinical manifestations of hyperkalemia in adults"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">DETERMINING THE URGENCY OF THERAPY</span><span class="headingEndMark"> — </span>The urgency of treatment of hyperkalemia varies with the presence or absence of the symptoms and signs associated with hyperkalemia, the severity of the potassium elevation, and the cause of hyperkalemia.</p><p>Our approach to therapeutic urgency is as follows  (<a class="graphic graphic_algorithm graphicRef109740" href="/z/d/graphic/109740.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperkalemic emergency</strong> – In general, the following patients should be considered to have a hyperkalemic emergency and should therefore be treated with rapidly acting therapies (ie, intravenous calcium, insulin, and glucose) in addition to therapies that remove potassium from the body (such as hemodialysis, gastrointestinal potassium binders, or diuretics) (see <a class="local">'Patients with a hyperkalemic emergency'</a> below):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who have clinical signs or symptoms of hyperkalemia. The most serious manifestations of hyperkalemia are muscle weakness or paralysis, cardiac conduction abnormalities, and cardiac arrhythmias, including sinus bradycardia, sinus arrest, slow idioventricular rhythms, ventricular tachycardia, ventricular fibrillation, and asystole. These manifestations usually occur when the serum potassium concentration is ≥7 mEq/L with chronic hyperkalemia, or possibly at lower levels in patients with an acute rise in serum potassium and/or underlying cardiac conduction disease. (See  <a class="medical medical_review" href="/z/d/html/2342.html" rel="external">"Clinical manifestations of hyperkalemia in adults"</a>.)</p><p></p><p class="bulletIndent2">There are several characteristic electrocardiogram (ECG) abnormalities associated with hyperkalemia  (<a class="graphic graphic_figure graphicRef109443" href="/z/d/graphic/109443.html" rel="external">figure 1</a>). A tall peaked T wave with a shortened QT interval is the earliest change  (<a class="graphic graphic_waveform graphicRef80441" href="/z/d/graphic/80441.html" rel="external">waveform 1</a>), followed by progressive lengthening of the PR interval and QRS duration  (<a class="graphic graphic_waveform graphicRef63569" href="/z/d/graphic/63569.html" rel="external">waveform 2</a>). The P wave may disappear, and ultimately, the QRS widens further to a sine wave. Ventricular standstill with a flat line on the ECG ensues with complete absence of electrical activity. The progression and severity of ECG changes do not correlate well with the serum potassium concentration. Conduction abnormalities, such as bundle branch blocks and arrhythmias (sinus bradycardia, sinus arrest, slow idioventricular rhythms, ventricular tachycardia, ventricular fibrillation, pseudo-ST-elevation myocardial infarction, pseudo-Brugada patterns, and asystole) may also occur in hyperkalemia [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/2342.html" rel="external">"Clinical manifestations of hyperkalemia in adults", section on 'ECG changes'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with severe hyperkalemia (serum potassium greater than 6.5 mEq/L), especially if there is concurrent tissue breakdown or gastrointestinal bleeding, even if there are no clinical signs or symptoms.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Some patients with moderate hyperkalemia (&gt;5.5 mEq/L) who have significant kidney function impairment and marked, ongoing tissue breakdown (eg, rhabdomyolysis or crush injury, tumor lysis syndrome), ongoing potassium absorption (eg, from substantial gastrointestinal bleeding), or a significant nonanion gap metabolic acidosis or respiratory acidosis. Tissue breakdown can release large amounts of potassium from cells, which can lead to rapid and substantial elevations in serum potassium. Potassium absorption from the blood in the gastrointestinal tract or soft tissues can produce similar rapid increases in the serum potassium. Patients with a nongap acidosis or respiratory acidosis may develop severe hyperkalemia quickly if the acidosis worsens, or if they develop an additional superimposed metabolic or respiratory acidosis, particularly when kidney function is impaired. (See  <a class="medical medical_review" href="/z/d/html/7227.html" rel="external">"Crush-related acute kidney injury"</a> and  <a class="medical medical_review" href="/z/d/html/1154.html" rel="external">"Tumor lysis syndrome: Pathogenesis, clinical manifestations, definition, etiology and risk factors"</a> and  <a class="medical medical_review" href="/z/d/html/14036.html" rel="external">"Prevention and treatment of heme pigment-induced acute kidney injury (including rhabdomyolysis)"</a> and  <a class="medical medical_review" href="/z/d/html/2353.html" rel="external">"Potassium balance in acid-base disorders"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients needing prompt therapy</strong> – Some patients without a hyperkalemic emergency should, nonetheless, have their potassium lowered promptly (ie, within 6 to 12 hours). Such patients include hemodialysis patients who present outside of regular dialysis hours, patients with marginal kidney function and/or marginal urine output, or hyperkalemic patients who need to be optimized for surgery. Measures such as isotonic bicarbonate infusion, intravenous <a class="drug drug_general" data-topicid="8711" href="/z/d/drug information/8711.html" rel="external">5 percent dextrose in water</a> infusion overnight (to stimulate insulin in a fasting patient), or hemodialysis may be appropriate in these settings. Additional measures can include oral potassium binders or kaliuresis induced by intravenous <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> with diuretic therapy. (See <a class="local">'Patients who need prompt serum potassium reduction'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients who can have the potassium lowered slowly</strong> – Most patients with hyperkalemia have chronic, mild (≤5.5 mEq/L) or moderate (5.5 to 6.5 mEq/L) elevations in serum potassium due to chronic kidney disease (CKD) or the use of medications that inhibit the renin-angiotensin-aldosterone system ([RAAS] or both). Such patients do not require urgent lowering of the serum potassium and can often be treated with dietary modification, use of diuretics (if otherwise appropriate), treatment of chronic metabolic acidosis, or reversal of factors that can cause hyperkalemia (eg, nonsteroidal antiinflammatory drugs, hypovolemia). In some instances, drugs that inhibit the RAAS are reduced or discontinued, and drugs that remove potassium by gastrointestinal cation exchange are prescribed for chronic use. (See <a class="local">'Patients who can have the serum potassium lowered slowly'</a> below.)</p><p></p><p class="bulletIndent1"><span class="utd-adt-cnt utd-adt-pathwys utd-content-131204">(Related Pathway(s):  <a class="utd-content-131204" href="/pathway/131204?topicRef=2332&amp;source=see_link">Hyperkalemia: Treatment in adults</a>.)</span></p><p></p><p class="headingAnchor" id="H3"><span class="h1">PATIENTS WITH A HYPERKALEMIC EMERGENCY</span><span class="headingEndMark"> — </span>Identifying patients who have a hyperkalemic emergency is presented above  (<a class="graphic graphic_algorithm graphicRef109740" data-inline-graphics="109740" href="/z/d/graphic/109740.html" rel="external">algorithm 1</a>). (See <a class="local">'Determining the urgency of therapy'</a> above.)</p><p>A table summarizing the initial assessment and management of patients with a hyperkalemic emergency is provided  (<a class="graphic graphic_table graphicRef74169" href="/z/d/graphic/74169.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H462542914"><span class="h2">Treatment approach to hyperkalemic emergencies</span><span class="headingEndMark"> — </span>Patients with a hyperkalemic emergency should generally receive  (<a class="graphic graphic_table graphicRef74169" data-inline-graphics="74169" href="/z/d/graphic/74169.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef52694" href="/z/d/graphic/52694.html" rel="external">table 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous calcium to antagonize the membrane actions of hyperkalemia (if electrocardiogram (ECG) changes consistent with hyperkalemia are present). In addition, some experts give intravenous calcium to all patients with a potassium &gt;6.5 mEq/L (even if notable ECG changes are absent), an approach supported by the Kidney Disease: Improving Global Outcomes (KDIGO) expert panel [<a href="#rid1">1</a>]. However, other experts administer intravenous calcium only if ECG abnormalities associated with hyperkalemia are present. (See <a class="local">'Calcium'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous insulin (typically given with intravenous glucose to avoid hypoglycemia) to drive extracellular potassium into cells. (See <a class="local">'Insulin with glucose'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Therapy to rapidly remove excess potassium from the body (ie, loop or thiazide diuretics if kidney function is not severely impaired, a gastrointestinal cation exchanger, and/or dialysis [preferably hemodialysis] if kidney function is severely impaired). (See <a class="local">'Remove potassium from the body'</a> below.)</p><p></p><p class="bulletIndent1">Urgent nephrology consultation to coordinate these therapies is appropriate in patients with a hyperkalemic emergency in the setting of kidney function impairment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of reversible causes of hyperkalemia, such as correcting hypovolemia and discontinuing drugs that increase the serum potassium (eg, nonsteroidal antiinflammatory drugs, inhibitors of the renin-angiotensin-aldosterone system)  (<a class="graphic graphic_table graphicRef58157" href="/z/d/graphic/58157.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef82440" href="/z/d/graphic/82440.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/z/d/html/2377.html" rel="external">"Causes and evaluation of hyperkalemia in adults"</a> and <a class="local">'Drug-induced hyperkalemia'</a> below.)</p><p></p><p><span class="utd-adt-cnt utd-adt-pathwys utd-content-131204">(Related Pathway(s):  <a class="utd-content-131204" href="/pathway/131204?topicRef=2332&amp;source=see_link">Hyperkalemia: Treatment in adults</a>.)</span></p><p>Intravenous calcium and insulin are rapidly acting treatments that provide time for the initiation of therapies that remove the excess potassium from the body  (<a class="graphic graphic_table graphicRef74169" href="/z/d/graphic/74169.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H4"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>Continuous cardiac monitoring and serial ECGs are warranted in patients with hyperkalemia who require rapidly acting therapies. The serum potassium should be measured at one to two hours after the initiation of treatment. The timing of further measurements is determined by the serum potassium concentration and the response to therapy. Patients who receive insulin, with or without dextrose, should undergo hourly glucose measurements for up to six hours in order to monitor for hypoglycemia.</p><p class="headingAnchor" id="H2727859129"><span class="h2">Administer rapidly acting therapies</span></p><p class="headingAnchor" id="H5"><span class="h3">Calcium</span><span class="headingEndMark"> — </span>Calcium directly antagonizes the membrane actions of hyperkalemia [<a href="#rid5">5</a>], while hypocalcemia increases the cardiotoxicity of hyperkalemia [<a href="#rid6">6</a>]. As discussed elsewhere, hyperkalemia-induced depolarization of the resting membrane potential leads to inactivation of sodium channels and decreased membrane excitability. (See  <a class="medical medical_review" href="/z/d/html/2342.html" rel="external">"Clinical manifestations of hyperkalemia in adults", section on 'Pathogenesis'</a>.)</p><p>The effect of intravenous calcium administration begins within minutes but is relatively short lived (30 to 60 minutes). As a result, calcium should not be administered as monotherapy for hyperkalemia but should rather be combined with therapies that drive extracellular potassium into cells. Administration of calcium can be repeated every 30 to 60 minutes if the hyperkalemic emergency persists and the serum calcium does not become elevated. (See <a class="local">'Insulin with glucose'</a> below.)</p><p>Calcium can be given as either <a class="drug drug_general" data-topicid="9190" href="/z/d/drug information/9190.html" rel="external">calcium gluconate</a> or <a class="drug drug_general" data-topicid="9186" href="/z/d/drug information/9186.html" rel="external">calcium chloride</a>. Calcium chloride contains three times the concentration of elemental calcium compared with calcium gluconate (13.6 versus 4.6 mEq in 10 mL of a 10 percent solution). However, calcium gluconate is generally preferred because calcium chloride may cause local irritation at the injection site [<a href="#rid3">3</a>].</p><p>The usual dose of <a class="drug drug_general" data-topicid="9190" href="/z/d/drug information/9190.html" rel="external">calcium gluconate</a> is 1000 mg (10 mL of a 10 percent solution) infused over two to three minutes, with constant cardiac monitoring. The usual dose of <a class="drug drug_general" data-topicid="9186" href="/z/d/drug information/9186.html" rel="external">calcium chloride</a> is 500 to 1000 mg (5 to 10 mL of a 10 percent solution), also infused over two to three minutes, with constant cardiac monitoring. The dose of either formulation can be repeated after five minutes if the ECG changes persist or recur.</p><p>Concentrated calcium infusions (particularly <a class="drug drug_general" data-topicid="9186" href="/z/d/drug information/9186.html" rel="external">calcium chloride</a>) are irritating to veins, and extravasation can cause tissue necrosis. As a result, a central or deep vein is preferred for administration of calcium chloride. <a class="drug drug_general" data-topicid="9190" href="/z/d/drug information/9190.html" rel="external">Calcium gluconate</a> can be given peripherally, ideally through a small needle or catheter in a large vein. Calcium should <strong>not</strong> be given in bicarbonate-containing solutions, which can lead to the precipitation of <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">calcium carbonate</a>.</p><p>When hyperkalemia occurs in patients treated with digitalis, calcium should be administered for the same indications as in patients not treated with digitalis (eg, widening of the QRS complex or loss of P waves) even though hypercalcemia potentiates the cardiotoxic effects of digitalis. In such patients, a dilute solution can be administered slowly, infusing 10 mL of 10 percent <a class="drug drug_general" data-topicid="9190" href="/z/d/drug information/9190.html" rel="external">calcium gluconate</a> in 100 mL of <a class="drug drug_general" data-topicid="8711" href="/z/d/drug information/8711.html" rel="external">5 percent dextrose in water</a> over 20 to 30 minutes, to avoid acute hypercalcemia [<a href="#rid2">2</a>]. In patients with hyperkalemia due to digitalis toxicity, the administration of digoxin-specific antibody fragments is the preferred therapy. (See  <a class="medical medical_review" href="/z/d/html/319.html" rel="external">"Digitalis (cardiac glycoside) poisoning", section on 'Electrolyte abnormalities'</a>.)</p><p class="headingAnchor" id="H6"><span class="h3">Insulin with glucose</span><span class="headingEndMark"> — </span>Insulin administration lowers the serum potassium concentration by driving potassium into the cells, primarily by enhancing the activity of the Na-K-ATPase pump in skeletal muscle [<a href="#rid2">2,7</a>]. Glucose is usually given with insulin to prevent the development of hypoglycemia. However, insulin should be given alone if the serum glucose is ≥250 mg/dL (13.9 mmol/L) [<a href="#rid8">8</a>]. The serum glucose should be measured every hour for five to six hours after the administration of insulin, given the risk of hypoglycemia.</p><p>The potassium-lowering effect of insulin is greatest at the high insulin levels achieved by a bolus injection. Administration of 10 units of <a class="drug drug_general" data-topicid="9030" href="/z/d/drug information/9030.html" rel="external">regular insulin</a>, followed immediately by 50 mL of 50 percent dextrose (25 g of glucose) leads to a relatively rapid reduction in serum potassium by approximately 1 mEq/L. However, high insulin levels, which are required for the maximal hypokalemic effect, are not sustained long after a single 10 unit bolus [<a href="#rid9">9,10</a>]. Yet the insulin levels remain high enough to cause hypoglycemia, which occurred in 6 to 19 percent of patients in two studies [<a href="#rid11">11,12</a>]. Thus, when glucose is given as a single bolus, hypoglycemia often develops an hour or more after the start of therapy for two reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>The amount of glucose in a single bolus is insufficient to replace the glucose utilized in response to exogenous insulin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Insulin's prolonged half-life in patients with kidney disease leads to insulin levels high enough to promote glucose utilization for more than an hour.</p><p></p><p>The incidence of hypoglycemia depends more upon the dose of glucose than upon the dose of insulin [<a href="#rid9">9,10</a>]. To avoid hypoglycemia, we recommend infusion of 10 percent dextrose at 50 to 75 mL/hour after the initial 25 g bolus and close monitoring of blood glucose levels every hour for five to six hours.</p><p>The administration of glucose without insulin is <strong>not</strong> recommended, since the release of endogenous insulin can be variable and the attained insulin levels are generally lower with a glucose infusion alone [<a href="#rid13">13</a>]. Furthermore, in susceptible patients (primarily diabetic patients with hyporeninemic hypoaldosteronism), hypertonic glucose in the absence of insulin may acutely increase the serum potassium concentration by raising the plasma osmolality, which promotes water and potassium movement out of the cells [<a href="#rid14">14-16</a>].</p><p>The effect of insulin begins in 10 to 20 minutes, peaks at 30 to 60 minutes, and lasts for four to six hours [<a href="#rid17">17-20</a>]. In almost all patients, the serum potassium concentration drops by 0.5 to 1.2 mEq/L [<a href="#rid20">20-23</a>]. In particular, although patients with kidney failure are resistant to the glucose-lowering effect of insulin, they are not resistant to the hypokalemic effect, because Na-K-ATPase activity is still enhanced [<a href="#rid24">24,25</a>]. (See  <a class="medical medical_review" href="/z/d/html/1974.html" rel="external">"Carbohydrate and insulin metabolism in chronic kidney disease"</a>.)</p><p class="headingAnchor" id="H3160641758"><span class="h4">Repeated dosing</span><span class="headingEndMark"> — </span>Removal of excess potassium from the body (eg, with hemodialysis or a gastrointestinal cation exchanger) is sometimes not feasible or must be delayed. Such patients can be treated with either a continuous infusion of insulin and glucose or bolus infusions of insulin with glucose, repeated every two to four hours, with serial monitoring of blood glucose levels. Compared with single-dose management, the risk of hypoglycemia is higher with repeated doses [<a href="#rid12">12</a>].  </p><p class="headingAnchor" id="H1575322125"><span class="h2">Remove potassium from the body</span><span class="headingEndMark"> — </span>The effective modalities described above only transiently lower the serum potassium concentration. Thus, additional therapy is typically required to remove excess potassium from the body, except in patients who have reversible hyperkalemia resulting from increased potassium release from cells due, for example, to metabolic acidosis or insulin deficiency and hyperglycemia. (See  <a class="medical medical_review" href="/z/d/html/2377.html" rel="external">"Causes and evaluation of hyperkalemia in adults", section on 'Increased potassium release from cells'</a>.)</p><p>The three available modalities for potassium removal are diuretics, gastrointestinal cation exchangers (eg, <a class="drug drug_general" data-topicid="104961" href="/z/d/drug information/104961.html" rel="external">patiromer</a>, <a class="drug drug_general" data-topicid="9936" href="/z/d/drug information/9936.html" rel="external">sodium polystyrene sulfonate</a> [SPS], and <a class="drug drug_general" data-topicid="117928" href="/z/d/drug information/117928.html" rel="external">sodium zirconium cyclosilicate</a> [SZC]), and dialysis (which, if available, is the most efficient method to remove potassium). In patients with a hyperkalemic emergency, diuretics should <strong>not</strong> be the only method used to remove potassium from the body.</p><p class="headingAnchor" id="H1185865100"><span class="h3">Loop diuretics in patients without severe kidney function impairment</span><span class="headingEndMark"> — </span>Loop diuretics increase potassium loss in the urine in patients with normal or mild to moderately impaired kidney function, particularly when combined with <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> hydration to maintain distal sodium delivery and flow. However, patients with persistent hyperkalemia typically have impaired renal potassium secretion, and there are no data demonstrating a clinically important short-term kaliuretic response to diuretic therapy. Thus, diuretics should <strong>not</strong> be used as the only means to remove potassium from the body in patients with a hyperkalemic emergency.</p><p>In hypervolemic patients with preserved kidney function (eg, patients with heart failure), we administer 40 mg of intravenous <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> every 12 hours or a continuous furosemide infusion. In euvolemic or hypovolemic patients with preserved kidney function, we administer isotonic <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> at a rate that is appropriate to replete hypovolemia and maintain euvolemia, followed by 40 mg of intravenous furosemide every 12 hours or a continuous furosemide infusion.</p><p>If kidney function is not preserved, we use a combination of an intravenous isotonic bicarbonate or isotonic <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> infusion plus intravenous <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> at doses that are appropriate for the patient's kidney function. (See  <a class="medical medical_review" href="/z/d/html/2310.html" rel="external">"Loop diuretics: Dosing and major side effects"</a>.)</p><p class="headingAnchor" id="H1910656954"><span class="h3">Dialysis and gastrointestinal cation exchangers</span><span class="headingEndMark"> — </span>Gastrointestinal cation exchangers, including <a class="drug drug_general" data-topicid="104961" href="/z/d/drug information/104961.html" rel="external">patiromer</a>, SZC, and SPS, bind potassium in the gastrointestinal tract in exchange for other cations, such as sodium or calcium. Such therapies can be used to treat hyperkalemia in patients with or without severe kidney function impairment.</p><p class="headingAnchor" id="H1521826299"><span class="h4">Hemodialysis in patients with severe kidney dysfunction</span><span class="headingEndMark"> — </span>Urgent nephrology consultation is appropriate for all patients with a hyperkalemic emergency and kidney function impairment (regardless of severity). Hemodialysis is indicated in hyperkalemic patients with severe kidney function impairment, and is preferable to cation exchangers if the patient has functioning vascular access for dialysis and if the procedure can be performed without delay. However, if hemodialysis cannot be performed promptly (eg, within six hours), we administer gastrointestinal cation exchange therapy (preferably <strong>not</strong> SPS) and then perform hemodialysis as soon as possible.</p><p class="headingAnchor" id="H3078611944"><span class="h4">Patiromer or sodium zirconium cyclosilicate (SZC)</span><span class="headingEndMark"> — </span>When using a cation exchanger in patients with a hyperkalemic emergency, we use SZC (10 g three times daily for 48 hours) or <a class="drug drug_general" data-topicid="104961" href="/z/d/drug information/104961.html" rel="external">patiromer</a> (8.4 g, repeated daily as needed) rather than SPS. If available, SZC is generally preferred over patiromer because of its more rapid onset of action. Both SZC and patiromer can acutely reduce serum potassium in patients with hyperkalemic emergency [<a href="#rid26">26,27</a>], although data are somewhat limited. The hypokalemic effect of SZC, for example, can be appreciated within one hour, with a mean reduction in serum potassium of 0.37 mEq/L four hours after a 10 g dose [<a href="#rid28">28</a>]. Our approach to dosing is based upon short-term effects of these drugs in a separate patient population (ie, those treated for chronic moderate hyperkalemia). (See <a class="local">'Patiromer'</a> below and <a class="local">'Sodium zirconium cyclosilicate (SZC)'</a> below.)</p><p class="headingAnchor" id="H2861995333"><span class="h4">Sodium polystyrene sulfonate (SPS) in rare settings</span><span class="headingEndMark"> — </span>We do <strong>not</strong> use <a class="drug drug_general" data-topicid="9936" href="/z/d/drug information/9936.html" rel="external">sodium polystyrene sulfonate</a> (SPS) if <a class="drug drug_general" data-topicid="104961" href="/z/d/drug information/104961.html" rel="external">patiromer</a> or SZC are available [<a href="#rid29">29,30</a>]. If necessary, SPS can lower the serum potassium in patients presenting with a hyperkalemic emergency [<a href="#rid31">31,32</a>]. In one retrospective uncontrolled study, for example, 501 patients with acute hyperkalemia were treated with 15 to 60 g of SPS; serum potassium decreased by a mean of 0.93 mEq/L by the time the serum potassium was measured again (typically within 24 hours) [<a href="#rid32">32</a>]. However, adverse effects were common and two patients developed bowel necrosis, a well-described complication of SPS [<a href="#rid33">33-37</a>].</p><p>SPS with or without <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">sorbitol</a> should <strong>not</strong> be given to the following patients because they may be at high risk for intestinal necrosis [<a href="#rid34">34,35,38,39</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Postoperative patients</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with an ileus </p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a large or small bowel obstruction</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with constipation or at risk of becoming constipated (eg, due to opioid use)</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with underlying bowel disease, eg, ulcerative colitis or <em>Clostridioides difficile</em> colitis</p><p></p><p>Even if restoration of kidney function or dialysis is not possible or immediately available, SPS should <strong>not</strong> be given in these high-risk settings; if other cation exchangers are not available, such patients can be managed with repeated doses of insulin and glucose (or continuous infusions) until dialysis can be performed. Other measures include the administration of isotonic bicarbonate and high-dose diuretics (if there is residual urine output). (See <a class="local">'Sodium bicarbonate'</a> below.)</p><p>Thus, we suggest that SPS be used (in conjunction with the rapidly acting transient therapies mentioned above) <strong>only</strong> in a patient who meets <strong>all</strong> of the following criteria:</p><p class="bulletIndent1"><span class="glyph">●</span>Patient has potentially life-threatening hyperkalemia</p><p class="bulletIndent1"><span class="glyph">●</span>Dialysis is not readily available</p><p class="bulletIndent1"><span class="glyph">●</span>Newer cation exchangers (ie, <a class="drug drug_general" data-topicid="104961" href="/z/d/drug information/104961.html" rel="external">patiromer</a> or SZC) are not available</p><p class="bulletIndent1"><span class="glyph">●</span>Other therapies to remove potassium (eg, diuretics, rapid restoration of kidney function) have failed or are not possible</p><p></p><p>In addition, if SPS is used, other orally administered drugs should be taken at least three hours before or three hours after the dose of SPS [<a href="#rid40">40</a>]. SPS binds to and prevents the absorption of many common medications.</p><p>The majority of intestinal necrosis cases associated with SPS occurred when the resin was administered with <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">sorbitol</a> [<a href="#rid33">33-37</a>]. In addition, intestinal necrosis was induced in a rat model by sorbitol alone or by sorbitol mixed with SPS but not with SPS alone [<a href="#rid36">36</a>]. Thus, it was presumed that sorbitol was required for the intestinal injury. As a result, the US Food and Drug Association (FDA) issued a recommendation in September 2009 that SPS should no longer be administered in sorbitol<strong> </strong>[<a href="#rid33">33</a>]. Despite this, many hospitals and pharmacies only stock <a class="drug drug_general" data-topicid="9936" href="/z/d/drug information/9936.html" rel="external">sodium polystyrene sulfonate</a> premixed in sorbitol. SPS alone is not always available and, when available, comes as a powder that must be reconstituted.</p><p>However, the association of SPS in <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">sorbitol</a> with intestinal necrosis may be coincidental since sorbitol is so widely used in conjunction with SPS. In addition, contemporary studies have found that SPS alone can cause intestinal necrosis in rats and have suggested that the previously noted toxicity of sorbitol alone in rats may have resulted from the hypertonic solution in which it was suspended [<a href="#rid41">41</a>].</p><p>Multiple clinical cases of intestinal necrosis with SPS and similar cation exchange resins without <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">sorbitol</a> have been reported [<a href="#rid42">42-45</a>]. Intestinal necrosis has also been reported in patients receiving SPS in a reduced concentration (33 percent) of sorbitol [<a href="#rid33">33</a>]. Evidence of gastrointestinal toxicity with SPS has also been noted in large observational studies:</p><p class="bulletIndent1"><span class="glyph">●</span>In a propensity-matched case-control study of more than 40,000 older adults spanning periods before and after the recommendation against mixing SPS with <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">sorbitol</a> [<a href="#rid46">46</a>], the incidence of serious adverse gastrointestinal events at 30 days, defined as hospitalization or emergency evaluation for intestinal ischemia, thrombosis, ulceration, perforation, resection, or ostomy, was twice as high among those treated with SPS compared with those who were not (0.2 versus 0.1 percent; hazard ratio 1.94, 95% CI 1.10-3.41).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A Swedish study of 19,530 SPS-naïve patients with stage 4 or 5 chronic kidney disease (CKD), including patients with end-stage kidney disease (ESKD), identified 202 severe and 1149 minor gastrointestinal events among 3690 patients who received SPS without <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">sorbitol</a> [<a href="#rid47">47</a>]. Initiation of SPS was associated with a higher incidence of severe adverse events (adjusted hazard ratio 1.25, 95% CI 1.05-1.49), primarily ulcers and perforations. Most patients (85 percent) were given lower dosages than specified on the product label, and patients receiving higher doses had a higher incidence of adverse events. Notably, SPS is commonly prescribed on a chronic basis to dialysis patients in Sweden (20 to 25 percent) and France (40 to 45 percent), while in the United Kingdom and the United States, SPS is prescribed to less than 5 percent of dialysis patients.</p><p></p><p>Thus, intestinal injury appears to be an important complication of SPS and is likely independent of <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">sorbitol</a>.</p><p>If given, SPS with or without <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">sorbitol</a> can be administered orally, and SPS without sorbitol can be administered as a retention enema. Oral dosing is probably more effective if intestinal motility is not impaired. The oral dose is usually 15 to 30 g, which can be repeated every four to six hours as necessary. Single doses are probably less effective [<a href="#rid48">48</a>].</p><p>If given as an enema, 50 g of SPS is mixed with 150 mL of tap water (<strong>not</strong> <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">sorbitol</a>). After cleansing enema with tap water at body temperature, the resin emulsion should be administered at body temperature through a rubber tube placed at approximately 20 cm from the rectum with the tip well into the sigmoid colon. The emulsion should be introduced by gravity and flushed with an additional 50 to 100 mL of non-sodium-containing fluid. The emulsion should be kept in the colon for at least 30 to 60 minutes and, preferably, two to four hours, followed by a cleansing enema (250 to 1000 mL of tap water at body temperature) [<a href="#rid49">49</a>]. The enema can be repeated every two to four hours, as necessary.</p><p class="headingAnchor" id="H3553483189"><span class="h2">Other therapies</span><span class="headingEndMark"> — </span>Beta-2-adrenergic agonists (eg, inhaled <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a>) and intravenous <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a> have been studied as potential rapidly acting therapies to reduce the serum potassium in hyperkalemic patients. Although they can be used in addition to calcium, insulin (with glucose), and potassium removal therapy, they should <strong>not</strong> be used in place of these treatments.</p><p class="headingAnchor" id="H7"><span class="h3">Beta-2-adrenergic agonists</span><span class="headingEndMark"> — </span>Given the potential adverse effects described below, the authors and reviewers of this topic believe that intravenous <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> should <strong>not</strong> be used in the treatment of hyperkalemia. <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">Albuterol</a> is not frequently used but can be considered as transient therapy in patients who have symptoms or serious ECG manifestations of hyperkalemia despite therapy with calcium and insulin with glucose, or in patients in whom dialysis is not appropriate or not feasible.</p><p>Like insulin, the beta-2-adrenergic agonists drive potassium into the cells by increasing the activity of the Na-K-ATPase pump in skeletal muscle [<a href="#rid2">2,50</a>]. Beta-2-adrenergic receptors in skeletal muscle also activate the inwardly directed Na-K-2Cl cotransporter, which may account for as much as one-third of the uptake response to catecholamines [<a href="#rid51">51</a>].</p><p>Beta-2-adrenergic agonists can be effective in the acute treatment of hyperkalemia, lowering the serum potassium concentration by 0.5 to 1.5 mEq/L [<a href="#rid13">13,17,22,52,53</a>]. <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">Albuterol</a>, which is relatively selective for the beta-2-adrenergic receptors, can be given as 10 to 20 mg in 4 mL of <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> by nebulization over 10 minutes (which is 4 to 8 times the dose used for bronchodilation). Alternatively and where available, albuterol 0.5 mg can be administered by intravenous infusion. In patients who cannot tolerate nebulized albuterol, and if intravenous therapy is not available, subcutaneous <a class="drug drug_general" data-topicid="9977" href="/z/d/drug information/9977.html" rel="external">terbutaline</a> is a potential alternative [<a href="#rid53">53</a>]. The peak effect is seen within 30 minutes with intravenous infusion and at 90 minutes with nebulization [<a href="#rid52">52</a>].</p><p><a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">Albuterol</a> and insulin with glucose have an additive effect, reducing serum potassium concentration by approximately 1.2 to 1.5 mEq/L [<a href="#rid17">17,20,54</a>]. Thus, although albuterol should not be used as monotherapy in hyperkalemic patients with ESKD, it can be added to insulin plus glucose to maximize the reduction in serum potassium [<a href="#rid17">17</a>]. One problem in patients on maintenance hemodialysis is that lowering the serum potassium concentration by driving potassium into the cells can diminish subsequent potassium removal during the dialysis session (from 50 to 29 mEq in one report), possibly leading to rebound hyperkalemia after dialysis [<a href="#rid55">55</a>].</p><p>Potential side effects of the beta-2 agonists include mild tachycardia and the possible induction of angina in susceptible subjects. Thus, these agents should probably be avoided in patients with active coronary disease. In addition, all patients with ESKD should be monitored carefully since they may have subclinical or overt coronary disease. (See  <a class="medical medical_review" href="/z/d/html/1960.html" rel="external">"Risk factors and epidemiology of coronary heart disease in end-stage kidney disease (dialysis)"</a>.)</p><p class="headingAnchor" id="H8"><span class="h3">Sodium bicarbonate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">Sodium bicarbonate</a> has limited efficacy in lowering the serum potassium in the acute setting, even in patients with metabolic acidosis [<a href="#rid22">22,56-58</a>]; therefore, we do not use bicarbonate therapy as the only treatment in the acute management of hyperkalemia.</p><p>Raising the systemic pH with <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a> results in hydrogen ion release from the cells as part of the buffering reaction. This change is accompanied by potassium movement into the cells to maintain electroneutrality. The use of bicarbonate for the treatment of hyperkalemia was mainly based upon small uncontrolled clinical studies [<a href="#rid59">59-61</a>]. However, in a study that compared different potassium-lowering modalities in 10 patients undergoing maintenance hemodialysis, a bicarbonate infusion (isotonic or hypertonic) for up to 60 minutes had no effect on the serum potassium concentration [<a href="#rid22">22</a>]. This lack of benefit was confirmed in several subsequent studies of hemodialysis patients [<a href="#rid56">56-58</a>].</p><p>However, bicarbonate therapy appears to be beneficial in patients with metabolic acidosis, particularly when administered as an isotonic infusion rather than bolus ampules of hypertonic <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a> [<a href="#rid22">22</a>]. In one series, for example, the administration of isotonic sodium bicarbonate in a constant infusion to patients with a baseline serum bicarbonate of 18 mEq/L had little effect at one and two hours but significantly lowered the serum potassium from 6 mEq/L at baseline to 5.4 and 5.3 mEq/L at four and six hours, respectively; the serum bicarbonate increased to 28 mEq/L at one hour and 30 mEq/L at six hours [<a href="#rid57">57</a>].</p><p>In addition, acute or chronic bicarbonate (alkali) therapy may be warranted to treat acidemia independent of hyperkalemia [<a href="#rid60">60</a>]. (See  <a class="medical medical_review" href="/z/d/html/2291.html" rel="external">"Approach to the adult with metabolic acidosis", section on 'Overview of therapy'</a> and  <a class="medical medical_review" href="/z/d/html/2293.html" rel="external">"Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease"</a>.)</p><p>When bicarbonate is given in the acute setting, we recommend the administration of an isotonic solution (eg, 150 mEq in 1 L of <a class="drug drug_general" data-topicid="8711" href="/z/d/drug information/8711.html" rel="external">5 percent dextrose in water</a> over two to four hours), assuming the patient can tolerate the volume load. There is a potential hazard of giving hypertonic solutions, such as the standard ampule of 50 mEq of <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a> in 50 mL. In addition, multiple doses can lead to hypernatremia [<a href="#rid22">22</a>].</p><p>Over the long term, in patients with chronic kidney disease (CKD), there are a variety of benefits from treating metabolic acidosis, and alkali therapy is recommended to maintain a near-normal serum bicarbonate, independent of any effect on the serum potassium concentration. (See  <a class="medical medical_review" href="/z/d/html/2293.html" rel="external">"Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease", section on 'Treatment of metabolic acidosis in CKD'</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">PATIENTS WITHOUT A HYPERKALEMIC EMERGENCY</span><span class="headingEndMark"> — </span>Identifying patients who do <strong>not</strong> have a hyperkalemic emergency is presented above. (See <a class="local">'Determining the urgency of therapy'</a> above.)</p><p>Patients who do not have a hyperkalemic emergency can generally be divided into two groups  (<a class="graphic graphic_algorithm graphicRef109740" href="/z/d/graphic/109740.html" rel="external">algorithm 1</a>) (see <a class="local">'Determining the urgency of therapy'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span>Those who, despite needing to have their potassium lowered promptly, do not require rapidly acting therapy with calcium and insulin with glucose. Such patients with severe kidney function impairment are typically treated with dialysis (preferably hemodialysis) with or without the use of a gastrointestinal cation exchanger (eg, <a class="drug drug_general" data-topicid="104961" href="/z/d/drug information/104961.html" rel="external">patiromer</a>). In patients with normal kidney function or mild to moderate kidney function impairment, correcting the cause of hyperkalemia (eg, drugs, hypovolemia) will generally suffice, in addition to treatment with <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> infusion and loop diuretics.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Those who can safely have their serum potassium lowered slowly. Such patients can usually be treated with therapies that gradually reduce the serum potassium, such as a low-potassium diet, loop or thiazide diuretics, or a reduction or cessation of medicines that can increase the serum potassium. With the introduction of <a class="drug drug_general" data-topicid="104961" href="/z/d/drug information/104961.html" rel="external">patiromer</a> and <a class="drug drug_general" data-topicid="117928" href="/z/d/drug information/117928.html" rel="external">sodium zirconium cyclosilicate</a> (SZC), it is anticipated that gastrointestinal cation exchangers will be utilized more frequently in these patients for chronic control of the serum potassium.</p><p></p><p><span class="utd-adt-cnt utd-adt-pathwys utd-content-131204">(Related Pathway(s):  <a class="utd-content-131204" href="/pathway/131204?topicRef=2332&amp;source=see_link">Hyperkalemia: Treatment in adults</a>.)</span></p><p class="headingAnchor" id="H2812736444"><span class="h2">Patients who need prompt serum potassium reduction</span><span class="headingEndMark"> — </span>Identifying patients who should have their serum potassium promptly lowered but who do not require rapidly acting therapy (ie, calcium and insulin with glucose), is presented above. (See <a class="local">'Determining the urgency of therapy'</a> above.) <span class="utd-adt-cnt utd-adt-pathwys utd-content-131204">(Related Pathway(s):  <a class="utd-content-131204" href="/pathway/131204?topicRef=2332&amp;source=see_link">Hyperkalemia: Treatment in adults</a>.)</span></p><p class="headingAnchor" id="H3025120161"><span class="h3">Those with severe kidney function impairment</span><span class="headingEndMark"> — </span>In patients with severe kidney function impairment who need prompt serum potassium reduction (ie, within 6 to 12 hours), dialysis should be performed right away if it is logistically feasible (ie, regular working hours, availability of staff, and presence of a suitable vascular access). Hemodialysis can normalize the serum potassium within four hours [<a href="#rid62">62</a>]. If prompt dialysis is not logistically feasible, then a gastrointestinal cation exchanger (preferably <a class="drug drug_general" data-topicid="104961" href="/z/d/drug information/104961.html" rel="external">patiromer</a> or SZC, if and when available) can be used to remove potassium from the body until such time that dialysis can be performed. (See <a class="local">'Gastrointestinal cation exchangers'</a> below.)</p><p class="headingAnchor" id="H4066960824"><span class="h4">Dialysis</span><span class="headingEndMark"> — </span>Dialysis is indicated in hyperkalemic patients with severe kidney function impairment. Hemodialysis is preferred since the rate of potassium removal is many times faster than with peritoneal dialysis [<a href="#rid63">63</a>]. Hemodialysis can remove 25 to 50 mEq of potassium per hour, with variability based upon the initial serum potassium concentration, the type and surface area of the dialyzer used, the blood flow rate, the dialysate flow rate, the duration of dialysis, the potassium concentration of the dialysate, and the patient's muscle mass [<a href="#rid2">2,18</a>].</p><p>One of the major determinants of the rate of potassium removal is the potassium gradient between the plasma and dialysate. Issues related to the removal of potassium with hemodialysis and potential adverse effects are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1854.html" rel="external">"Acute hemodialysis prescription"</a>.)</p><p>A rebound increase in serum potassium concentration occurs after hemodialysis in all patients in whom potassium is removed since the reduction in serum potassium during dialysis creates a gradient for potassium movement out of the cells. The magnitude of this effect was evaluated in a study of 14 stable maintenance hemodialysis patients [<a href="#rid64">64</a>]. The average serum potassium concentrations at baseline, during hemodialysis, and up to six hours after hemodialysis were 5.7, 3.6, and 5 mEq/L, respectively. Thus, the serum potassium concentration should usually not be measured soon after the completion of hemodialysis, since the results are likely to be misleading.</p><p>The postdialysis rebound after hemodialysis is more pronounced in patients undergoing acute hemodialysis for hyperkalemia due to massive release of potassium from injured cells (eg, tumor lysis, rhabdomyolysis) and after regular maintenance hemodialysis in patients with a high predialysis serum potassium concentration [<a href="#rid64">64</a>].</p><p>Rapidly acting transient therapies given before dialysis, such as insulin with glucose or <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a>, have a twofold effect: Total potassium removal is reduced due to lowering of the serum potassium concentration [<a href="#rid55">55,65</a>]; and the potassium rebound is greater because of the wearing off of the effect of the transient therapies. The potassium rebound is also increased with a high-sodium dialysate since the increase in plasma osmolality creates a gradient for water and then potassium efflux from the cells [<a href="#rid66">66</a>].</p><p>Patients who have a large postdialysis rebound may require daily dialysis or continuous kidney replacement therapy to avoid recurrent severe hyperkalemia.</p><p class="headingAnchor" id="H2686782473"><span class="h3">Those without severe kidney function impairment</span><span class="headingEndMark"> — </span>Patients who have moderate hyperkalemia and either normal kidney function or mild to moderate kidney function impairment can usually be managed without dialysis. Treatment of such patients typically includes a gastrointestinal cation exchanger in addition to reversing the cause of hyperkalemia. As an example, a patient with moderate chronic kidney disease (CKD) treated with a renin-angiotensin-aldosterone system (RAAS) inhibitor who presents with a serum potassium of 6.0 mEq/L may be treated with a cation exchanger (such as <a class="drug drug_general" data-topicid="104961" href="/z/d/drug information/104961.html" rel="external">patiromer</a>), temporary discontinuation of the RAAS inhibitor, as well as other therapies that are appropriate for the clinical setting (ie, bicarbonate therapy if the patient has metabolic acidosis, and diuretic therapy if the patient is hypervolemic).</p><p class="headingAnchor" id="H3554397999"><span class="h2">Patients who can have the serum potassium lowered slowly</span><span class="headingEndMark"> — </span>Identifying patients who do not need prompt lowering of the serum potassium and can be safely treated with therapy that gradually lowers the serum potassium is presented above. (See <a class="local">'Determining the urgency of therapy'</a> above.)</p><p>Hyperkalemia can be corrected in these patients over a matter of days to weeks, depending upon the clinical circumstance. Serum potassium should be monitored over the equivalent time frame, so as to follow the response to therapy and detect iatrogenic hypokalemia.</p><p>In addition to correcting reversible causes of hyperkalemia, our approach in such patients is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>All such patients should receive dietary counseling to reduce potassium intake  (<a class="graphic graphic_table graphicRef82742" href="/z/d/graphic/82742.html" rel="external">table 5</a>). (See  <a class="medical medical_basics" href="/z/d/html/16441.html" rel="external">"Patient education: Low-potassium diet (The Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/4427.html" rel="external">"Patient education: Low-potassium diet (Beyond the Basics)"</a> and <a class="local">'Dietary modification'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In addition, thiazide or loop diuretics can be used in patients who have hypertension or hypervolemia. (See <a class="local">'Diuretics'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who continue to have moderate hyperkalemia despite dietary modification and diuretics can be treated chronically with newer gastrointestinal cation exchangers (eg, <a class="drug drug_general" data-topicid="104961" href="/z/d/drug information/104961.html" rel="external">patiromer</a>). (See <a class="local">'Gastrointestinal cation exchangers'</a> below.)</p><p></p><p><span class="utd-adt-cnt utd-adt-pathwys utd-content-131204">(Related Pathway(s):  <a class="utd-content-131204" href="/pathway/131204?topicRef=2332&amp;source=see_link">Hyperkalemia: Treatment in adults</a>.)</span></p><p class="headingAnchor" id="H714857357"><span class="h3">Dietary modification</span><span class="headingEndMark"> — </span>It is rare for hyperkalemia to occur exclusively due to excessive intake, although such cases have been described [<a href="#rid67">67,68</a>]. By contrast, the presence of kidney disease predisposes to hyperkalemia in patients consuming potassium [<a href="#rid69">69</a>]. In addition to kidney function impairment, other predisposing factors include hypoaldosteronism and drugs that inhibit the RAAS can result in significant hyperkalemia after only modest intake of potassium. Such patients should be assessed for their intake of potassium-rich foods (refer to https://www.kidney.org/atoz/content/potassium), and counseled to avoid these foods  (<a class="graphic graphic_table graphicRef53492" href="/z/d/graphic/53492.html" rel="external">table 6</a>). Other, occult sources of excessive potassium include salt substitutes [<a href="#rid70">70,71</a>], various forms of pica [<a href="#rid72">72</a>], and "alternative" nutritional therapies [<a href="#rid73">73,74</a>]. Often, the adoption of a potassium-restricted diet (refer to https://www.kidney.org/atoz/content/potassium) normalizes serum potassium levels and affords the resumption of RAAS antagonists  (<a class="graphic graphic_table graphicRef63021" href="/z/d/graphic/63021.html" rel="external">table 7</a>), even in patients with CKD.</p><p class="headingAnchor" id="H12"><span class="h3">Diuretics</span><span class="headingEndMark"> — </span>Loop and thiazide diuretics increase potassium loss in the urine in patients with normal or mild to moderately impaired kidney function, particularly when combined with <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> hydration to maintain distal sodium delivery and flow. However, patients with persistent hyperkalemia typically have impaired renal potassium secretion, and there are no data demonstrating a clinically important short-term kaliuretic response to diuretic therapy.</p><p>Although data are limited, chronic diuretic therapy is probably effective over the long term by increasing urinary potassium excretion, particularly in patients with mild to moderate CKD [<a href="#rid75">75</a>]. For patients with moderate hyperkalemia whose kidney function is not severely impaired, we suggest a trial of diuretics if otherwise appropriate (eg, hypertension or hypervolemia). Among patients with hyperkalemia due to angiotensin inhibitors, many can be controlled with a low-potassium diet and diuretic therapy.</p><p class="headingAnchor" id="H2928132632"><span class="h3">Gastrointestinal cation exchangers</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="104961" href="/z/d/drug information/104961.html" rel="external">Patiromer</a> and SZC are nonabsorbable compounds that exchange calcium or sodium and hydrogen, respectively. We do <strong>not</strong> use <a class="drug drug_general" data-topicid="9936" href="/z/d/drug information/9936.html" rel="external">sodium polystyrene sulfonate</a> (a cation exchange resin) as chronic therapy for such patients.</p><p class="headingAnchor" id="H2081489882"><span class="h4">Patiromer</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="104961" href="/z/d/drug information/104961.html" rel="external">Patiromer</a> is a spherical, nonabsorbable organic polymer, formulated as a powder for suspension, which binds potassium in the colon in exchange for calcium [<a href="#rid76">76,77</a>].</p><p>In a phase II, open-label dose-finding trial (AMETHYST-DN), 306 diabetic patients with an estimated glomerular filtration rate (eGFR) of 15 to 59 mL/min/1.73 m<sup>2</sup> and either mild or moderate hyperkalemia (serum potassium of 5.1 to 5.5, or 5.6 to 5.9 mEq/L, respectively) were randomly assigned to a range of initial <a class="drug drug_general" data-topicid="104961" href="/z/d/drug information/104961.html" rel="external">patiromer</a> doses (4.2 g twice daily to 16.8 g twice daily) [<a href="#rid78">78</a>]; follow-up was 52 weeks. All patients were also treated with stable doses of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB), or both, often in combination with <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>. At four weeks, the change in serum potassium from baseline ranged from -0.35 to -0.55 mEq/L with initial doses of 4.2 g twice daily to 12.6 g twice daily among those with mild hyperkalemia, and from -0.87 to -0.97 mEq/L with initial doses of 8.4 g twice daily to 12.6 g twice daily among those with moderate hyperkalemia. Approximately one-third of patients had a single adjustment (up or down) to their patiromer dose; most required no adjustment. At 52 weeks, serum potassium concentrations remained in the normal range with continued patiromer therapy. Discontinuation of patiromer resulted in an increase in the serum potassium within three days.</p><p>There were no treatment-related serious adverse events in AMETHYST-DN. The most common treatment-related side effects included constipation (6.3 percent of patients) and hypomagnesemia (8.6 percent of patients). Hypomagnesemia occurred more commonly with higher doses of <a class="drug drug_general" data-topicid="104961" href="/z/d/drug information/104961.html" rel="external">patiromer</a> (16.7 percent among those assigned 33.6 g/day compared with 5.4 percent among those assigned 8.4 g/day). Severe hypomagnesemia (a serum magnesium &lt;1.2 mg/dL) developed in 13 patients (4.3 percent).</p><p>The OPAL-HK study extended these observations in a phase III, randomized placebo-controlled trial in outpatients with CKD and hyperkalemia [<a href="#rid79">79</a>]. In OPAL-HK, 243 patients with an eGFR of 15 to 59 mL/min/1.73 m<sup>2</sup> and a serum potassium of 5.1 to 6.4 mEq/L on two occasions while receiving a stable dose of an ACE inhibitor or ARB received either 4.2 or 8.4 g of <a class="drug drug_general" data-topicid="104961" href="/z/d/drug information/104961.html" rel="external">patiromer</a> twice daily for four weeks, depending upon whether their serum potassium was below or above 5.5 mEq/L. The mean decrease in serum potassium at four weeks was 1.0 mEq/L (0.6 and 1.2 mEq/L with lower and higher doses, respectively); approximately 75 percent of patients achieved the target serum potassium of 3.8 to 5.0 mEq/L. The decline in serum potassium was steepest during the first three days.</p><p>The 107 patients whose baseline serum potassium was 5.5 mEq/L or greater and who achieved the target serum potassium during the initial four-week treatment period were randomly assigned to <a class="drug drug_general" data-topicid="104961" href="/z/d/drug information/104961.html" rel="external">patiromer</a> or placebo for another eight weeks. Serum potassium remained the same in patients continuing patiromer and increased by 0.7 mEq/L in those assigned to placebo. The incidence of hyperkalemia (5.5 mEq/L or greater) was significantly higher in the placebo group (60 versus 15 percent). Serious adverse events were rare and not likely to be related to treatment; constipation was the most common side effect, occurring in 11 percent of patients during the initial four-week period. As with the AMETHYST-DN trial, hypomagnesemia developed in some patients (eight patients [3 percent] developed magnesium levels &lt;1.4 mg/dL).</p><p>There are several limitations of the OPAL-HK and AMETHYST-DN trials. The effect of <a class="drug drug_general" data-topicid="104961" href="/z/d/drug information/104961.html" rel="external">patiromer</a> in patients with acute hyperkalemia or end-stage kidney disease (ESKD) was not evaluated, although this drug effectively reduced potassium among hemodialysis patients in a nonrandomized study [<a href="#rid80">80</a>]. In addition, patients in these trials were not routinely prescribed a low-potassium diet, only one-half of patients in the OPAL-HK trial were receiving loop or thiazide diuretics, and the number of patients in the AMETHYST-DN trial who received diuretics was not reported. Both a low-potassium diet and the use of loop or thiazide diuretics can be long-term strategies to prevent hyperkalemia in many patients with CKD who are treated with ACE inhibitors or ARBs. (See <a class="local">'Diuretics'</a> above.)</p><p><a class="drug drug_general" data-topicid="104961" href="/z/d/drug information/104961.html" rel="external">Patiromer</a> has been used successfully to minimize hyperkalemia in other patient groups, including those with resistant hypertension treated with <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> and those with heart failure with reduced ejection fraction (HFrEF) treated with several RAAS inhibitors [<a href="#rid81">81,82</a>]. (See  <a class="medical medical_review" href="/z/d/html/3819.html" rel="external">"Treatment of resistant hypertension"</a> and  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction"</a>.)</p><p>In addition to binding cations, <a class="drug drug_general" data-topicid="104961" href="/z/d/drug information/104961.html" rel="external">patiromer</a> can bind other drugs in the gastrointestinal tract. Clinically important interactions with <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a>, thyroxine, and <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> have been identified; these three drugs need to be administered more than three hours before or after patiromer [<a href="#rid83">83</a>].</p><p class="headingAnchor" id="H1165904747"><span class="h4">Sodium zirconium cyclosilicate (SZC)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="117928" href="/z/d/drug information/117928.html" rel="external">Sodium zirconium cyclosilicate</a> (also known as zirconium cyclosilicate, SZC, and ZS-9) is an inorganic, nonabsorbable crystalline compound that exchanges both sodium and hydrogen ions for potassium throughout its intestinal transit [<a href="#rid76">76</a>]. The efficacy of SZC in hyperkalemic outpatients was evaluated in two nearly identical phase III, randomized placebo-controlled trials:</p><p class="bulletIndent1"><span class="glyph">●</span>In the Hyperkalemia Randomized Intervention Multidose ZS-9 Maintenance (HARMONIZE) study, 258 adult patients with persistent hyperkalemia (serum potassium that is greater than or equal to 5.1 mEq/L) entered a 48-hour open-label run-in during which they received 10 g of SZC three times daily; 69 percent had CKD (although patients with ESKD were excluded), 70 percent were taking a renin-angiotensin system inhibitor, and the majority had heart failure, diabetes mellitus, or both [<a href="#rid84">84</a>]. Of the 258 patients who entered the open-label run-in, 237 (92 percent) achieved a normal serum potassium (3.5 to 5.0 mEq/L) at 48 hours and were then randomly assigned to placebo or 5 g, 10 g, or 15 g of SZC once daily for four weeks. During randomized therapy, the mean serum potassium was significantly lower with SZC (4.8, 4.5, and 4.4 mEq/L with 5, 10, and 15 g dosing, respectively) as compared with placebo (5.1 mEq/L). Similarly, the proportion of normokalemic patients at the end of the study was significantly greater with SZC (71 to 85 percent as compared with 48 percent with placebo). Serious adverse events were uncommon and were not significantly increased with SZC. However, edema was more common with the 10 g and 15 g doses compared with placebo (6 and 14 versus 2 percent), as was hypokalemia (10 and 11 versus 0 percent). Among a subgroup of 87 patients with heart failure, edema occurred in eight (15 percent) of those receiving SZC and in one (4 percent) receiving placebo [<a href="#rid85">85</a>]. Higher edema rates with SZC are likely due to an increased sodium load (which, as noted above, would be expected since SZC exchanges sodium for potassium).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another trial, 753 adult patients with a serum potassium of 5.0 to 6.5 mEq/L were randomly assigned to receive 1.25, 2.5, 5, or 10 g of SZC three times daily for 48 hours; 62 percent had CKD (patients with ESKD were excluded), 67 percent were receiving a renin-angiotensin system inhibitor, and most patients had diabetes, heart failure, or both [<a href="#rid28">28</a>]. A normal serum potassium (3.5 to 4.9 mEq/L) at 48 hours was attained by 543 patients (72 percent), and these individuals were then reassigned to receive placebo or 1.25, 2.5, 5, or 10 g of SZC once daily for two weeks. The serum potassium at two weeks was significantly lower in patients receiving 5 and 10 g doses of SZC as compared with placebo (by approximately 0.3 and 0.5 mEq/L, respectively) but not with 1.25 and 2.5 g doses. Adverse events were similar with placebo and SZC.</p><p></p><p>In these trials, the steepest decline in serum potassium with SZC occurred during the first four hours of therapy [<a href="#rid28">28,84</a>]. This suggests an acute effect on intestinal potassium secretion, rather than simply a reduction in potassium absorption.</p><p>The long-term efficacy of SZC was examined in an open-label trial of 751 outpatients with sustained hyperkalemia (5.1 mEq/L or greater); mean eGFR was 47 mL/min/1.73 m<sup>2</sup> and 65 percent were receiving a renin-angiotensin system inhibitor (ie, an ACE inhibitor, ARB, or mineralocorticoid receptor antagonist) [<a href="#rid86">86</a>]. Patients were treated with 10 g three times daily of SZC for three days; the serum potassium corrected to the normal range in 99 percent, and these patients received a maintenance dose of 5 to 15 g once daily for up to 12 months. During maintenance treatment, 88 percent had a mean serum potassium of 5.1 mEq/L or less, 87 percent of those taking a renin-angiotensin system inhibitor continued on these medications, and renin-angiotensin system inhibitors were initiated in 14 percent of those not taking them at baseline.</p><p>SZC is also effective for management of hyperkalemia among patients receiving maintenance hemodialysis. In the DIALYZE study, 196 patients receiving maintenance hemodialysis who had persistent predialysis hyperkalemia were randomly assigned to treatment with SZC (5 to 15 g orally on nondialysis days) or placebo for eight weeks [<a href="#rid87">87</a>]. Treatment success, defined as a predialysis serum potassium (following the long interdialytic interval) of 4.0 to 5.0 mEq/L during the last four weeks of therapy, was more common with SZC (41 versus 1 percent). However, the more clinically important endpoint of "rescue therapy," defined as an intervention (such as dialysis, insulin plus glucose, other cation exchangers) to urgently reduce the serum potassium, was infrequent in both groups and not statistically different (2 versus 5 percent). Adverse event rates were similar in both groups.</p><p class="headingAnchor" id="H13"><span class="h4">Do not use sodium polystyrene sulfonate (SPS) or other resins</span><span class="headingEndMark"> — </span>The most widely used cation exchange resin has been <a class="drug drug_general" data-topicid="9936" href="/z/d/drug information/9936.html" rel="external">sodium polystyrene sulfonate</a> (SPS). Although "SPS" is often used as an abbreviation for sodium polystyrene sulfonate, SPS is actually a brand name for sodium polystyrene sulfonate in <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">sorbitol</a>.</p><p>Cation exchange resins do not appear to be more effective in removing potassium from the body than laxative therapy. Although uncommon, cation exchange resins can produce severe side effects, particularly intestinal necrosis, which may be fatal. (See <a class="local">'Sodium polystyrene sulfonate (SPS) in rare settings'</a> above.)</p><p>Given these concerns, SPS or other resins should <strong>not</strong> be used in patients with chronic mild or moderate hyperkalemia who do not have a hyperkalemic emergency and who do not require a prompt reduction in serum potassium. (See <a class="local">'Determining the urgency of therapy'</a> above.)</p><p class="headingAnchor" id="H22"><span class="h1">DRUG-INDUCED HYPERKALEMIA</span><span class="headingEndMark"> — </span>A variety of drugs can raise the serum potassium, primarily by interfering with the renin-angiotensin-aldosterone system (RAAS). Probably the most common are angiotensin inhibitors (eg, angiotensin-converting enzyme [ACE] inhibitors and angiotensin II receptor blockers [ARBs]), aldosterone antagonists and other potassium sparing diuretics (eg, <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>, <a class="drug drug_general" data-topicid="8789" href="/z/d/drug information/8789.html" rel="external">eplerenone</a>, and <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">amiloride</a>), digitalis, and nonsteroidal antiinflammatory drugs  (<a class="graphic graphic_table graphicRef82440" href="/z/d/graphic/82440.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/z/d/html/2377.html" rel="external">"Causes and evaluation of hyperkalemia in adults", section on 'Reduced aldosterone secretion'</a>.) </p><p>These drugs should be discontinued, or the dose reduced, at least temporarily, until the hyperkalemia is controlled. </p><p>In patients with heart failure with reduced ejection fraction or albuminuric chronic kidney disease, it is important to resume therapeutic doses of RAAS antagonists since cessation or permanent dose reduction of these agents is associated with higher rates of mortality and adverse cardiovascular events [<a href="#rid88">88,89</a>]. (See  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction"</a> and  <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3052.html" rel="external">"Treatment of diabetic kidney disease"</a>.)</p><p>Strategies to prevent the recurrence of hyperkalemia when RAAS inhibition is reinstituted are presented below. (See <a class="local">'Prevention'</a> below.)</p><p>If hyperkalemia recurs, strategies other than RAAS inhibitor discontinuation should be implemented, as described above. (See <a class="local">'Patients who can have the serum potassium lowered slowly'</a> above.)</p><p class="headingAnchor" id="H23"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>There are several measures that can help to prevent hyperkalemia in patients with chronic kidney disease (CKD), particularly those with end-stage kidney disease (ESKD). In addition to a low-potassium diet, the following modalities have been effective in stable maintenance hemodialysis patients (see  <a class="medical medical_patient" href="/z/d/html/4427.html" rel="external">"Patient education: Low-potassium diet (Beyond the Basics)"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Avoid episodes of fasting, which can increase potassium movement out of the cells due, at least in part, to reduced insulin secretion [<a href="#rid13">13,90</a>]. In a study of 10 stable patients on maintenance hemodialysis who did not have diabetes mellitus, fasting for 18 hours led to a mean 0.6 mEq/L rise in the serum potassium concentration, which was completely prevented when the protocol was repeated with the administration of low-dose insulin with dextrose [<a href="#rid90">90</a>]. Thus, nondiabetic patients with ESKD who are undergoing elective surgery should, if they are in the hospital, receive parenteral glucose-containing solutions when fasting overnight.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoid, if possible, drugs that raise the serum potassium concentration in patients with a serum potassium ≥5.5 mEq/L. These include inhibitors of the renin-angiotensin-aldosterone system (RAAS), such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), direct renin inhibitors, aldosterone antagonists, and nonselective beta blockers (eg, <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> and <a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">labetalol</a>) [<a href="#rid91">91,92</a>]. Beta-1-selective blockers such as <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a> and <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a> are much less likely to cause hyperkalemia [<a href="#rid13">13,93</a>]. (See  <a class="medical medical_review" href="/z/d/html/2377.html" rel="external">"Causes and evaluation of hyperkalemia in adults", section on 'Beta blockers'</a>.)</p><p></p><p>Patients with CKD or heart failure are often treated with RAAS inhibitors. A variety of preventive measures can diminish the risk of hyperkalemia [<a href="#rid91">91</a>]. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Close monitoring of the serum potassium concentration and estimated glomerular filtration rate (eGFR), particularly after changes in RAAS inhibitor therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dietary restriction of potassium. (See  <a class="medical medical_patient" href="/z/d/html/4427.html" rel="external">"Patient education: Low-potassium diet (Beyond the Basics)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance or discontinuation of other drugs that impair potassium excretion (eg, nonsteroidal antiinflammatory drugs).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The utilization of low initial doses and evidence-based final doses of RAAS inhibitors for specific indications (eg, heart failure, proteinuric CKD). The dose should be reduced with moderate hyperkalemia (serum potassium of ≤5.5 mEq/L) and therapy should be discontinued if the serum potassium rises above 5.5 mEq/L unless the serum potassium can be reduced by diuretic therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The use of thiazide or loop diuretics whenever otherwise indicated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are no good data on the chronic efficacy of oral alkali therapy (<a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a> or sodium citrate) for the treatment of persistent hyperkalemia. Most such patients have CKD with or without hypoaldosteronism. There are a variety of benefits from treating metabolic acidosis in such patients, and alkali therapy is typically recommended, independent of any effect on the serum potassium concentration. (See  <a class="medical medical_review" href="/z/d/html/2293.html" rel="external">"Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease", section on 'Treatment of metabolic acidosis in CKD'</a>.)</p><p></p><p class="headingAnchor" id="H4152920255"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109733.html" rel="external">"Society guideline links: Fluid and electrolyte disorders in adults"</a>.)</p><p class="headingAnchor" id="H14910511"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/17129.html" rel="external">"Patient education: Hyperkalemia (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16441.html" rel="external">"Patient education: Low-potassium diet (The Basics)"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/4427.html" rel="external">"Patient education: Low-potassium diet (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H13967046"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Determining the urgency of treatment</strong> – The urgency of treatment of hyperkalemia varies with the presence or absence of the symptoms and signs associated with hyperkalemia, the severity of the potassium elevation, and the cause of hyperkalemia. Our approach to therapeutic urgency is as follows  (<a class="graphic graphic_algorithm graphicRef109740" href="/z/d/graphic/109740.html" rel="external">algorithm 1</a>) (see <a class="local">'Determining the urgency of therapy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hyperkalemic emergency − Patients who have clinical signs or symptoms of hyperkalemia (eg, muscle weakness or paralysis, cardiac conduction abnormalities, cardiac arrhythmias), patients with severe hyperkalemia (serum potassium &gt;6.5 mEq/L), and patients with moderate hyperkalemia (serum potassium &gt;5.5 mEq/L) plus significant kidney function impairment and ongoing tissue breakdown or potassium absorption) have a hyperkalemic emergency.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients needing prompt therapy − Some patients with moderate hyperkalemia but without a hyperkalemic emergency should, nonetheless, have their potassium lowered promptly (ie, within 6 to 12 hours). Such patients include hemodialysis patients who present outside of regular dialysis hours, patients with marginal kidney function and/or marginal urine output, or hyperkalemic patients who need to be optimized for surgery.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who can have the potassium lowered slowly − Most patients with hyperkalemia have chronic, mild (≤5.5 mEq/L) or moderate (5.5 to 6.5 mEq/L) elevations in serum potassium due to chronic kidney disease (CKD) or the use of medications that inhibit the renin-angiotensin-aldosterone system ([RAAS] or both). Such patients do not require urgent lowering of the serum potassium.</p><p></p><p class="bulletIndent1"><span class="utd-adt-cnt utd-adt-pathwys utd-content-131204">(Related Pathway(s):  <a class="utd-content-131204" href="/pathway/131204?topicRef=2332&amp;source=see_link">Hyperkalemia: Treatment in adults</a>.)</span></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with a hyperkalemic emergency</strong> – Patients with a hyperkalemic emergency should receive  (<a class="graphic graphic_table graphicRef74169" href="/z/d/graphic/74169.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef52694" href="/z/d/graphic/52694.html" rel="external">table 2</a>) (see <a class="local">'Patients with a hyperkalemic emergency'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intravenous calcium to antagonize the membrane actions of hyperkalemia if electrocardiogram (ECG) changes consistent with hyperkalemia are present. In addition, some, although not all, experts give intravenous calcium to patients with a potassium &gt;6.5 mEq/L (even if notable ECG changes are absent). (See <a class="local">'Calcium'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intravenous insulin (typically given with intravenous glucose) to drive extracellular potassium into cells. (See <a class="local">'Insulin with glucose'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Therapy to rapidly remove excess potassium from the body (ie, loop or thiazide diuretics if kidney function is not severely impaired, a gastrointestinal cation exchanger, and/or dialysis [preferably hemodialysis] if kidney function is severely impaired). (See <a class="local">'Remove potassium from the body'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Treatment of reversible causes of hyperkalemia, such as correcting hypovolemia and discontinuing drugs that increase the serum potassium (eg, nonsteroidal antiinflammatory drugs [NSAIDs], inhibitors of the RAAS). (See  <a class="medical medical_review" href="/z/d/html/2377.html" rel="external">"Causes and evaluation of hyperkalemia in adults"</a> and <a class="local">'Drug-induced hyperkalemia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Continuous cardiac monitoring and serial ECGs. The serum potassium should be measured at one to two hours after the initiation of treatment. The timing of further measurements is determined by the serum potassium concentration and the response to therapy. Patients who receive insulin, with or without dextrose, should undergo hourly glucose measurements for up to six hours in order to monitor for hypoglycemia. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="utd-adt-cnt utd-adt-pathwys utd-content-131204">(Related Pathway(s):  <a class="utd-content-131204" href="/pathway/131204?topicRef=2332&amp;source=see_link">Hyperkalemia: Treatment in adults</a>.)</span></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients without a hyperkalemic emergency</strong> – Treatment of patients who do not have a hyperkalemic emergency generally depends upon how promptly the serum potassium should be lowered  (<a class="graphic graphic_algorithm graphicRef109740" href="/z/d/graphic/109740.html" rel="external">algorithm 1</a>) (see <a class="local">'Patients without a hyperkalemic emergency'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients needing prompt potassium lowering are typically treated with hemodialysis (if they have severe kidney dysfunction) with or without the use of a gastrointestinal cation exchanger (preferably <a class="drug drug_general" data-topicid="117928" href="/z/d/drug information/117928.html" rel="external">sodium zirconium cyclosilicate</a> [SZC] or <a class="drug drug_general" data-topicid="104961" href="/z/d/drug information/104961.html" rel="external">patiromer</a>). In patients with normal kidney function or mild to moderate kidney function impairment, correcting the cause of hyperkalemia (eg, drugs, hypovolemia) will generally suffice, in addition to treatment with <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> infusion and loop diuretics; a gastrointestinal cation exchanger is sometimes used in such patients. (See <a class="local">'Patients who need prompt serum potassium reduction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who can safely have their serum potassium lowered slowly are usually treated with therapies that gradually reduce the serum potassium, such as a low-potassium diet, loop or thiazide diuretics, or a reduction or cessation of medicines that can increase the serum potassium. With the introduction of <a class="drug drug_general" data-topicid="104961" href="/z/d/drug information/104961.html" rel="external">patiromer</a> and SZC, it is anticipated that gastrointestinal cation exchangers will be utilized more frequently in these patients for chronic control of the serum potassium. (See <a class="local">'Patients who can have the serum potassium lowered slowly'</a> above.)</p><p></p><p class="bulletIndent1"><span class="utd-adt-cnt utd-adt-pathwys utd-content-131204">(Related Pathway(s):  <a class="utd-content-131204" href="/pathway/131204?topicRef=2332&amp;source=see_link">Hyperkalemia: Treatment in adults</a>.)</span></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – There are several measures that can help to prevent hyperkalemia or worsening of hyperkalemia in patients with CKD, particularly those with end-stage kidney disease (ESKD). In addition to a low-potassium diet, the following modalities have been effective in stable maintenance hemodialysis patients (see <a class="local">'Prevention'</a> above and  <a class="medical medical_patient" href="/z/d/html/4427.html" rel="external">"Patient education: Low-potassium diet (Beyond the Basics)"</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Avoid episodes of fasting, which can increase potassium movement out of the cells due, at least in part, to reduced insulin secretion.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with moderate hyperkalemia, avoid, if possible, drugs that raise the serum potassium concentration. These include RAAS inhibitors, such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), direct renin inhibitors, aldosterone antagonists, and nonselective beta blockers (eg, <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> and <a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">labetalol</a>)  (<a class="graphic graphic_table graphicRef82440" href="/z/d/graphic/82440.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Avoidance or discontinuation of other drugs that impair potassium excretion (eg, NSAIDs).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The use of thiazide or loop diuretics whenever otherwise indicated.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Clase CM, Carrero JJ, Ellison DH, et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2020; 97:42.</a></li><li class="breakAll">Mount DB. Disorders of potassium balance. In: Brenner and Rector's The Kidney, 11th ed, Yu A, Chertow G, Luyckx V, et al (Eds), W.B. Saunders &amp; Company, Philadelphia 2020. p.537.</li><li><a class="nounderline abstract_t">Long B, Warix JR, Koyfman A. Controversies in Management of Hyperkalemia. J Emerg Med 2018; 55:192.</a></li><li><a class="nounderline abstract_t">Littmann L, Gibbs MA. Electrocardiographic manifestations of severe hyperkalemia. J Electrocardiol 2018; 51:814.</a></li><li><a class="nounderline abstract_t">Winkler AW, Hoff HE, Smith PK. Factors affecting the toxicity of potassium. Am J Physiol 1939; 127:430.</a></li><li><a class="nounderline abstract_t">BRAUN HA, VAN HORNE R, BETTINGER JC, BELLET S. The influence of hypocalcemia induced by sodium ethylenediamine tetraacetate on the toxicity of potassium; an experimental study. J Lab Clin Med 1955; 46:544.</a></li><li><a class="nounderline abstract_t">Ferrannini E, Taddei S, Santoro D, et al. Independent stimulation of glucose metabolism and Na+-K+ exchange by insulin in the human forearm. Am J Physiol 1988; 255:E953.</a></li><li class="breakAll">Pergola PE, DeFronzo R. Clinical disorders of hyperkalemia. In: The Kidney: Physiology and Pathophysiology, Seldin DW, Giebisch G (Eds), Lippincott Williams &amp; Wilkins, 2000. Vol 2, p.1647.</li><li><a class="nounderline abstract_t">Harel Z, Kamel KS. Optimal Dose and Method of Administration of Intravenous Insulin in the Management of Emergency Hyperkalemia: A Systematic Review. PLoS One 2016; 11:e0154963.</a></li><li><a class="nounderline abstract_t">Sterns RH, Grieff M, Bernstein PL. Treatment of hyperkalemia: something old, something new. Kidney Int 2016; 89:546.</a></li><li><a class="nounderline abstract_t">Tee SA, Devine K, Potts A, et al. Iatrogenic hypoglycaemia following glucose-insulin infusions for the treatment of hyperkalaemia. Clin Endocrinol (Oxf) 2021; 94:176.</a></li><li><a class="nounderline abstract_t">Humphrey TJL, James G, Wilkinson IB, Hiemstra TF. Clinical outcomes associated with the emergency treatment of hyperkalaemia with intravenous insulin-dextrose. Eur J Intern Med 2022; 95:87.</a></li><li><a class="nounderline abstract_t">Allon M. Hyperkalemia in end-stage renal disease: mechanisms and management. J Am Soc Nephrol 1995; 6:1134.</a></li><li><a class="nounderline abstract_t">Goldfarb S, Strunk B, Singer I, Goldberg M. Paradoxical glucose-induced hyperkalemia. Combined aldosterone-insulin deficiency. Am J Med 1975; 59:744.</a></li><li><a class="nounderline abstract_t">Nicolis GL, Kahn T, Sanchez A, Gabrilove JL. Glucose-induced hyperkalemia in diabetic subjects. Arch Intern Med 1981; 141:49.</a></li><li><a class="nounderline abstract_t">Magnus Nzerue C, Jackson E. Intractable life-threatening hyperkalaemia in a diabetic patient. Nephrol Dial Transplant 2000; 15:113.</a></li><li><a class="nounderline abstract_t">Allon M, Copkney C. Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. Kidney Int 1990; 38:869.</a></li><li><a class="nounderline abstract_t">Ahmed J, Weisberg LS. Hyperkalemia in dialysis patients. Semin Dial 2001; 14:348.</a></li><li><a class="nounderline abstract_t">Kim HJ, Han SW. Therapeutic approach to hyperkalemia. Nephron 2002; 92 Suppl 1:33.</a></li><li><a class="nounderline abstract_t">Lens XM, Montoliu J, Cases A, et al. Treatment of hyperkalaemia in renal failure: salbutamol v. insulin. Nephrol Dial Transplant 1989; 4:228.</a></li><li><a class="nounderline abstract_t">Emmett M. Non-dialytic treatment of acute hyperkalemia in the dialysis patient. Semin Dial 2000; 13:279.</a></li><li><a class="nounderline abstract_t">Blumberg A, Weidmann P, Shaw S, Gnädinger M. Effect of various therapeutic approaches on plasma potassium and major regulating factors in terminal renal failure. Am J Med 1988; 85:507.</a></li><li><a class="nounderline abstract_t">De Wolf A, Frenette L, Kang Y, Tang C. Insulin decreases the serum potassium concentration during the anhepatic stage of liver transplantation. Anesthesiology 1993; 78:677.</a></li><li><a class="nounderline abstract_t">Alvestrand A, Wahren J, Smith D, DeFronzo RA. Insulin-mediated potassium uptake is normal in uremic and healthy subjects. Am J Physiol 1984; 246:E174.</a></li><li><a class="nounderline abstract_t">Goecke IA, Bonilla S, Marusic ET, Alvo M. Enhanced insulin sensitivity in extrarenal potassium handling in uremic rats. Kidney Int 1991; 39:39.</a></li><li><a class="nounderline abstract_t">Rafique Z, Liu M, Staggers KA, et al. Patiromer for Treatment of Hyperkalemia in the Emergency Department: A Pilot Study. Acad Emerg Med 2020; 27:54.</a></li><li><a class="nounderline abstract_t">Peacock WF, Rafique Z, Vishnevskiy K, et al. Emergency Potassium Normalization Treatment Including Sodium Zirconium Cyclosilicate: A Phase II, Randomized, Double-blind, Placebo-controlled Study (ENERGIZE). Acad Emerg Med 2020; 27:475.</a></li><li><a class="nounderline abstract_t">Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med 2015; 372:222.</a></li><li><a class="nounderline abstract_t">Gupta AA, Self M, Mueller M, et al. Dispelling myths and misconceptions about the treatment of acute hyperkalemia. Am J Emerg Med 2022; 52:85.</a></li><li><a class="nounderline abstract_t">Rossignol P, Pitt B. Sodium polystyrene is unsafe and should not be prescribed for the treatment of hyperkalaemia: primum non nocere! Clin Kidney J 2023; 16:1221.</a></li><li><a class="nounderline abstract_t">Mistry M, Shea A, Giguère P, Nguyen ML. Evaluation of Sodium Polystyrene Sulfonate Dosing Strategies in the Inpatient Management of Hyperkalemia. Ann Pharmacother 2016; 50:455.</a></li><li><a class="nounderline abstract_t">Hagan AE, Farrington CA, Wall GC, Belz MM. Sodium polystyrene sulfonate for the treatment of acute hyperkalemia: a retrospective study. Clin Nephrol 2016; 85:38.</a></li><li><a class="nounderline abstract_t">Sterns RH, Rojas M, Bernstein P, Chennupati S. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol 2010; 21:733.</a></li><li><a class="nounderline abstract_t">Gerstman BB, Kirkman R, Platt R. Intestinal necrosis associated with postoperative orally administered sodium polystyrene sulfonate in sorbitol. Am J Kidney Dis 1992; 20:159.</a></li><li><a class="nounderline abstract_t">McGowan CE, Saha S, Chu G, et al. Intestinal necrosis due to sodium polystyrene sulfonate (Kayexalate) in sorbitol. South Med J 2009; 102:493.</a></li><li><a class="nounderline abstract_t">Lillemoe KD, Romolo JL, Hamilton SR, et al. Intestinal necrosis due to sodium polystyrene (Kayexalate) in sorbitol enemas: clinical and experimental support for the hypothesis. Surgery 1987; 101:267.</a></li><li><a class="nounderline abstract_t">Rashid A, Hamilton SR. Necrosis of the gastrointestinal tract in uremic patients as a result of sodium polystyrene sulfonate (Kayexalate) in sorbitol: an underrecognized condition. Am J Surg Pathol 1997; 21:60.</a></li><li><a class="nounderline abstract_t">Scott TR, Graham SM, Schweitzer EJ, Bartlett ST. Colonic necrosis following sodium polystyrene sulfonate (Kayexalate)-sorbitol enema in a renal transplant patient. Report of a case and review of the literature. Dis Colon Rectum 1993; 36:607.</a></li><li><a class="nounderline abstract_t">Wootton FT, Rhodes DF, Lee WM, Fitts CT. Colonic necrosis with Kayexalate-sorbitol enemas after renal transplantation. Ann Intern Med 1989; 111:947.</a></li><li class="breakAll">https://www.fda.gov/Drugs/DrugSafety/ucm572484.htm.</li><li><a class="nounderline abstract_t">Ayoub I, Oh MS, Gupta R, et al. Colon Necrosis Due to Sodium Polystyrene Sulfonate with and without Sorbitol: An Experimental Study in Rats. PLoS One 2015; 10:e0137636.</a></li><li><a class="nounderline abstract_t">Cheng ES, Stringer KM, Pegg SP. Colonic necrosis and perforation following oral sodium polystyrene sulfonate (Resonium A/Kayexalate in a burn patient. Burns 2002; 28:189.</a></li><li><a class="nounderline abstract_t">Goutorbe P, Montcriol A, Lacroix G, et al. Intestinal Necrosis Associated with Orally Administered Calcium Polystyrene Sulfonate Without Sorbitol. Ann Pharmacother 2011; 45:e13.</a></li><li><a class="nounderline abstract_t">Rugolotto S, Gruber M, Solano PD, et al. Necrotizing enterocolitis in a 850 gram infant receiving sorbitol-free sodium polystyrene sulfonate (Kayexalate): clinical and histopathologic findings. J Perinatol 2007; 27:247.</a></li><li><a class="nounderline abstract_t">Joo M, Bae WK, Kim NH, Han SR. Colonic mucosal necrosis following administration of calcium polystryrene sulfonate (Kalimate) in a uremic patient. J Korean Med Sci 2009; 24:1207.</a></li><li><a class="nounderline abstract_t">Noel JA, Bota SE, Petrcich W, et al. Risk of Hospitalization for Serious Adverse Gastrointestinal Events Associated With Sodium Polystyrene Sulfonate Use in Patients of Advanced Age. JAMA Intern Med 2019; 179:1025.</a></li><li><a class="nounderline abstract_t">Laureati P, Xu Y, Trevisan M, et al. Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: a nationwide study. Nephrol Dial Transplant 2020; 35:1518.</a></li><li><a class="nounderline abstract_t">Gruy-Kapral C, Emmett M, Santa Ana CA, et al. Effect of single dose resin-cathartic therapy on serum potassium concentration in patients with end-stage renal disease. J Am Soc Nephrol 1998; 9:1924.</a></li><li><a class="nounderline abstract_t">Gales MA, Gales BJ, Dyer ME, Orr SR. Rectally administered sodium polystyrene sulfonate. Am J Health Syst Pharm 1995; 52:2813.</a></li><li><a class="nounderline abstract_t">Clausen T, Everts ME. Regulation of the Na,K-pump in skeletal muscle. Kidney Int 1989; 35:1.</a></li><li><a class="nounderline abstract_t">Gosmanov AR, Wong JA, Thomason DB. Duality of G protein-coupled mechanisms for beta-adrenergic activation of NKCC activity in skeletal muscle. Am J Physiol Cell Physiol 2002; 283:C1025.</a></li><li><a class="nounderline abstract_t">Liou HH, Chiang SS, Wu SC, et al. Hypokalemic effects of intravenous infusion or nebulization of salbutamol in patients with chronic renal failure: comparative study. Am J Kidney Dis 1994; 23:266.</a></li><li><a class="nounderline abstract_t">Sowinski KM, Cronin D, Mueller BA, Kraus MA. Subcutaneous terbutaline use in CKD to reduce potassium concentrations. Am J Kidney Dis 2005; 45:1040.</a></li><li><a class="nounderline abstract_t">Ahee P, Crowe AV. The management of hyperkalaemia in the emergency department. J Accid Emerg Med 2000; 17:188.</a></li><li><a class="nounderline abstract_t">Allon M, Shanklin N. Effect of albuterol treatment on subsequent dialytic potassium removal. Am J Kidney Dis 1995; 26:607.</a></li><li><a class="nounderline abstract_t">Gutierrez R, Schlessinger F, Oster JR, et al. Effect of hypertonic versus isotonic sodium bicarbonate on plasma potassium concentration in patients with end-stage renal disease. Miner Electrolyte Metab 1991; 17:297.</a></li><li><a class="nounderline abstract_t">Blumberg A, Weidmann P, Ferrari P. Effect of prolonged bicarbonate administration on plasma potassium in terminal renal failure. Kidney Int 1992; 41:369.</a></li><li><a class="nounderline abstract_t">Allon M, Shanklin N. Effect of bicarbonate administration on plasma potassium in dialysis patients: interactions with insulin and albuterol. Am J Kidney Dis 1996; 28:508.</a></li><li><a class="nounderline abstract_t">BURNELL JM, SCRIBNER BH, UYENO BT, VILLAMIL MF. The effect in humans of extracellular pH change on the relationship between serum potassium concentration and intracellular potassium. J Clin Invest 1956; 35:935.</a></li><li><a class="nounderline abstract_t">SCHWARZ KC, COHEN BD, LUBASH GD, RUBIN AL. Severe acidosis and hyperpotassemia treated with sodium bicarbonate infusion. Circulation 1959; 19:215.</a></li><li><a class="nounderline abstract_t">Fraley DS, Adler S. Correction of hyperkalemia by bicarbonate despite constant blood pH. Kidney Int 1977; 12:354.</a></li><li><a class="nounderline abstract_t">Peacock WF, Rafique Z, Clark CL, et al. Real World Evidence for Treatment of Hyperkalemia in the Emergency Department (REVEAL-ED): A Multicenter, Prospective, Observational Study. J Emerg Med 2018; 55:741.</a></li><li><a class="nounderline abstract_t">Nolph KD, Popovich RP, Ghods AJ, Twardowski Z. Determinants of low clearances of small solutes during peritoneal dialysis. Kidney Int 1978; 13:117.</a></li><li><a class="nounderline abstract_t">Blumberg A, Roser HW, Zehnder C, Müller-Brand J. Plasma potassium in patients with terminal renal failure during and after haemodialysis; relationship with dialytic potassium removal and total body potassium. Nephrol Dial Transplant 1997; 12:1629.</a></li><li><a class="nounderline abstract_t">Allon M. Medical and dialytic management of hyperkalemia in hemodialysis patients. Int J Artif Organs 1996; 19:697.</a></li><li><a class="nounderline abstract_t">De Nicola L, Bellizzi V, Minutolo R, et al. Effect of dialysate sodium concentration on interdialytic increase of potassium. J Am Soc Nephrol 2000; 11:2337.</a></li><li><a class="nounderline abstract_t">John SK, Rangan Y, Block CA, Koff MD. Life-threatening hyperkalemia from nutritional supplements: uncommon or undiagnosed? Am J Emerg Med 2011; 29:1237.e1.</a></li><li><a class="nounderline abstract_t">Parisi A, Alabiso A, Sacchetti M, et al. Complex ventricular arrhythmia induced by overuse of potassium supplementation in a young male football player. Case report. J Sports Med Phys Fitness 2002; 42:214.</a></li><li><a class="nounderline abstract_t">Smillie WG. Potassium poisoning in nephritis. Arch Intern Med 1915; 16:330.</a></li><li><a class="nounderline abstract_t">Doorenbos CJ, Vermeij CG. Danger of salt substitutes that contain potassium in patients with renal failure. BMJ 2003; 326:35.</a></li><li><a class="nounderline abstract_t">Sopko JA, Freeman RM. Salt substitutes as a source of potassium. JAMA 1977; 238:608.</a></li><li><a class="nounderline abstract_t">Abu-Hamdan DK, Sondheimer JH, Mahajan SK. Cautopyreiophagia. Cause of life-threatening hyperkalemia in a patient undergoing hemodialysis. Am J Med 1985; 79:517.</a></li><li><a class="nounderline abstract_t">Nagasaki A, Takamine W, Takasu N. Severe hyperkalemia associated with "alternative" nutritional cancer therapy. Clin Nutr 2005; 24:864.</a></li><li><a class="nounderline abstract_t">Mueller BA, Scott MK, Sowinski KM, Prag KA. Noni juice (Morinda citrifolia): hidden potential for hyperkalemia? Am J Kidney Dis 2000; 35:310.</a></li><li><a class="nounderline abstract_t">Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med 1998; 158:26.</a></li><li><a class="nounderline abstract_t">Ingelfinger JR. A new era for the treatment of hyperkalemia? N Engl J Med 2015; 372:275.</a></li><li><a class="nounderline abstract_t">Bushinsky DA, Spiegel DM, Gross C, et al. Effect of Patiromer on Urinary Ion Excretion in Healthy Adults. Clin J Am Soc Nephrol 2016; 11:1769.</a></li><li><a class="nounderline abstract_t">Bakris GL, Pitt B, Weir MR, et al. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial. JAMA 2015; 314:151.</a></li><li><a class="nounderline abstract_t">Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 2015; 372:211.</a></li><li><a class="nounderline abstract_t">Amdur RL, Paul R, Barrows ED, et al. The potassium regulator patiromer affects serum and stool electrolytes in patients receiving hemodialysis. Kidney Int 2020; 98:1331.</a></li><li><a class="nounderline abstract_t">Agarwal R, Rossignol P, Romero A, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2019; 394:1540.</a></li><li><a class="nounderline abstract_t">Butler J, Anker SD, Lund LH, et al. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. Eur Heart J 2022; 43:4362.</a></li><li><a class="nounderline abstract_t">Lesko LJ, Offman E, Brew CT, et al. Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers. J Cardiovasc Pharmacol Ther 2017; 22:434.</a></li><li><a class="nounderline abstract_t">Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA 2014; 312:2223.</a></li><li><a class="nounderline abstract_t">Anker SD, Kosiborod M, Zannad F, et al. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail 2015; 17:1050.</a></li><li><a class="nounderline abstract_t">Spinowitz BS, Fishbane S, Pergola PE, et al. Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study. Clin J Am Soc Nephrol 2019; 14:798.</a></li><li><a class="nounderline abstract_t">Fishbane S, Ford M, Fukagawa M, et al. A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia. J Am Soc Nephrol 2019; 30:1723.</a></li><li><a class="nounderline abstract_t">Leon SJ, Whitlock R, Rigatto C, et al. Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study. Am J Kidney Dis 2022; 80:164.</a></li><li><a class="nounderline abstract_t">Linde C, Bakhai A, Furuland H, et al. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom. J Am Heart Assoc 2019; 8:e012655.</a></li><li><a class="nounderline abstract_t">Allon M, Takeshian A, Shanklin N. Effect of insulin-plus-glucose infusion with or without epinephrine on fasting hyperkalemia. Kidney Int 1993; 43:212.</a></li><li><a class="nounderline abstract_t">Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004; 351:585.</a></li><li><a class="nounderline abstract_t">Knoll GA, Sahgal A, Nair RC, et al. Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Am J Med 2002; 112:110.</a></li><li><a class="nounderline abstract_t">Castellino P, Bia MJ, DeFronzo RA. Adrenergic modulation of potassium metabolism in uremia. Kidney Int 1990; 37:793.</a></li></ol></div><div id="topicVersionRevision">Topic 2332 Version 56.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31706619" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31706619" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29731287" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Controversies in Management of Hyperkalemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30177318" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Electrocardiographic manifestations of severe hyperkalemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Factors affecting the toxicity of potassium</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13263734" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The influence of hypocalcemia induced by sodium ethylenediamine tetraacetate on the toxicity of potassium; an experimental study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2849310" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Independent stimulation of glucose metabolism and Na+-K+ exchange by insulin in the human forearm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2849310" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Independent stimulation of glucose metabolism and Na+-K+ exchange by insulin in the human forearm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27148740" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Optimal Dose and Method of Administration of Intravenous Insulin in the Management of Emergency Hyperkalemia: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26880451" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Treatment of hyperkalemia: something old, something new.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32979855" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Iatrogenic hypoglycaemia following glucose-insulin infusions for the treatment of hyperkalaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34625340" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical outcomes associated with the emergency treatment of hyperkalaemia with intravenous insulin-dextrose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8589279" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Hyperkalemia in end-stage renal disease: mechanisms and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1200041" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Paradoxical glucose-induced hyperkalemia. Combined aldosterone-insulin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7447584" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Glucose-induced hyperkalemia in diabetic subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10607780" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Intractable life-threatening hyperkalaemia in a diabetic patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2266671" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11679104" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Hyperkalemia in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12401936" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Therapeutic approach to hyperkalemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2498781" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Treatment of hyperkalaemia in renal failure: salbutamol v. insulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11014688" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Non-dialytic treatment of acute hyperkalemia in the dialysis patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3052050" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effect of various therapeutic approaches on plasma potassium and major regulating factors in terminal renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8466068" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Insulin decreases the serum potassium concentration during the anhepatic stage of liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6364842" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Insulin-mediated potassium uptake is normal in uremic and healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1672173" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Enhanced insulin sensitivity in extrarenal potassium handling in uremic rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31599043" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Patiromer for Treatment of Hyperkalemia in the Emergency Department: A Pilot Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32149451" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Emergency Potassium Normalization Treatment Including Sodium Zirconium Cyclosilicate: A Phase II, Randomized, Double-blind, Placebo-controlled Study (ENERGIZE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25415807" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Sodium zirconium cyclosilicate in hyperkalemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34890894" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Dispelling myths and misconceptions about the treatment of acute hyperkalemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37529653" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Sodium polystyrene is unsafe and should not be prescribed for the treatment of hyperkalaemia: primum non nocere!</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27048188" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Evaluation of Sodium Polystyrene Sulfonate Dosing Strategies in the Inpatient Management of Hyperkalemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26587776" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Sodium polystyrene sulfonate for the treatment of acute hyperkalemia: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20167700" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1496969" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Intestinal necrosis associated with postoperative orally administered sodium polystyrene sulfonate in sorbitol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19373153" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Intestinal necrosis due to sodium polystyrene sulfonate (Kayexalate) in sorbitol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3824154" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Intestinal necrosis due to sodium polystyrene (Kayexalate) in sorbitol enemas: clinical and experimental support for the hypothesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8990142" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Necrosis of the gastrointestinal tract in uremic patients as a result of sodium polystyrene sulfonate (Kayexalate) in sorbitol: an underrecognized condition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8500380" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Colonic necrosis following sodium polystyrene sulfonate (Kayexalate)-sorbitol enema in a renal transplant patient. Report of a case and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2817643" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Colonic necrosis with Kayexalate-sorbitol enemas after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2817643" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Colonic necrosis with Kayexalate-sorbitol enemas after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26413782" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Colon Necrosis Due to Sodium Polystyrene Sulfonate with and without Sorbitol: An Experimental Study in Rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11900946" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Colonic necrosis and perforation following oral sodium polystyrene sulfonate (Resonium A/Kayexalate in a burn patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21304040" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Intestinal Necrosis Associated with Orally Administered Calcium Polystyrene Sulfonate Without Sorbitol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17377608" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Necrotizing enterocolitis in a 850 gram infant receiving sorbitol-free sodium polystyrene sulfonate (Kayexalate): clinical and histopathologic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19949685" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Colonic mucosal necrosis following administration of calcium polystryrene sulfonate (Kalimate) in a uremic patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31180477" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Risk of Hospitalization for Serious Adverse Gastrointestinal Events Associated With Sodium Polystyrene Sulfonate Use in Patients of Advanced Age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31377791" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: a nationwide study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9773794" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effect of single dose resin-cathartic therapy on serum potassium concentration in patients with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8748567" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Rectally administered sodium polystyrene sulfonate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2540370" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Regulation of the Na,K-pump in skeletal muscle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12225966" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Duality of G protein-coupled mechanisms for beta-adrenergic activation of NKCC activity in skeletal muscle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8311086" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Hypokalemic effects of intravenous infusion or nebulization of salbutamol in patients with chronic renal failure: comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15957133" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Subcutaneous terbutaline use in CKD to reduce potassium concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10819381" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The management of hyperkalaemia in the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7573015" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Effect of albuterol treatment on subsequent dialytic potassium removal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1668124" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Effect of hypertonic versus isotonic sodium bicarbonate on plasma potassium concentration in patients with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1552710" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Effect of prolonged bicarbonate administration on plasma potassium in terminal renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8840939" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Effect of bicarbonate administration on plasma potassium in dialysis patients: interactions with insulin and albuterol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13367188" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The effect in humans of extracellular pH change on the relationship between serum potassium concentration and intracellular potassium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13629781" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Severe acidosis and hyperpotassemia treated with sodium bicarbonate infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24132" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Correction of hyperkalemia by bicarbonate despite constant blood pH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30391144" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Real World Evidence for Treatment of Hyperkalemia in the Emergency Department (REVEAL-ED): A Multicenter, Prospective, Observational Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/713273" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Determinants of low clearances of small solutes during peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9269640" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Plasma potassium in patients with terminal renal failure during and after haemodialysis; relationship with dialytic potassium removal and total body potassium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9029244" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Medical and dialytic management of hyperkalemia in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11095656" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Effect of dialysate sodium concentration on interdialytic increase of potassium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21075579" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Life-threatening hyperkalemia from nutritional supplements: uncommon or undiagnosed?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12032418" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Complex ventricular arrhythmia induced by overuse of potassium supplementation in a young male football player. Case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Potassium poisoning in nephritis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12511461" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Danger of salt substitutes that contain potassium in patients with renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/577961" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Salt substitutes as a source of potassium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4050837" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Cautopyreiophagia. Cause of life-threatening hyperkalemia in a patient undergoing hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16083995" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Severe hyperkalemia associated with "alternative" nutritional cancer therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10676732" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Noni juice (Morinda citrifolia): hidden potential for hyperkalemia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9437375" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25415806" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A new era for the treatment of hyperkalemia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27679518" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Effect of Patiromer on Urinary Ion Excretion in Healthy Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26172895" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25415805" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32750456" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The potassium regulator patiromer affects serum and stool electrolytes in patients receiving hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31533906" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35900838" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28585859" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25402495" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26011677" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31110051" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31201218" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35085685" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31711387" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8433561" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Effect of insulin-plus-glucose infusion with or without epinephrine on fasting hyperkalemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15295051" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11835948" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2308263" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Adrenergic modulation of potassium metabolism in uremia.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
